USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that ...
The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...
Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...
Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...
Sam Altman just said the quiet part out loud. The OpenAI CEO suggested the company could be less than six months away from achieving recursive self-improvement, a capability where AI systems can ...
Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...
As competition among AI companies intensifies, Anthropic is urging policymakers and researchers to consider how the world would respond if artificial intelligence reaches the point of self-improvement ...
One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...
Abstract: Fault detection has long been a hot research issue for industry. Many common algorithms such as principal component analysis, recursive transformed component statistical analysis and moments ...
Good afternoon, everyone, and thank you for joining us on the first day of Needham & Company Healthcare Conference. My name is Gil Blum, and I'm a senior biotech analyst here at Needham & Company. It ...